Amathumba e-Pancreatic neuroendocrine (NETs) ngokuvamile akhula kancane, futhi ilabhorethri iqapha isimila ukuze sithole izimpawu zokukhula ngokuhlolwa kwesithombe. Iziguli ezine-NET esabalele ngaphandle kwamanyikwe ngokuvamile ziba nezimpawu ezifana nesifo sohudo noma izinkinga zamahomoni. Angasetshenziselwa izidakamizwa ezifana ne-octreotide, i-lanreotide, i-diazoxide, ne-proton pump inhibitors, engavimbela ukukhula kwesimila.
When the patient’s symptoms cannot be controlled or the scan shows signs of isisu growth, further treatment is required, and chemotherapy or targeted drugs (such as sunitinib or everolimus) can be used. For people with poorly differentiated tumors (neuroendocrine carcinoma), chemotherapy is the first choice. For patients who have spread to the liver, choose surgery or ablation technology for treatment according to their own conditions. For adults with somatostatin (a hormone) receptor-positive pancreatic neuroendocrine tumor, the radiopharmaceutical Lutathera (l Lu177 dotatate) is a treatment option.
If all feasible treatments no longer work, then consider participating in clinical trials to test new therapies. Participation in clinical trials is likely to benefit some patients.
